Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

BACKGROUND: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of HER2-overexpressing breast cancer. We argue that the two anti-HER2 agents given together would be better than...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Baselga, José, Bradbury, Ian, Eidtmann, Holger, Di Cosimo, Serena, de Azambuja, Evandro, Aura, Claudia, Gómez, Henry, Dinh, Phuong, Fauria, Karine, Van Dooren, Veerle, Aktan, Gursel, Goldhirsch, Aron, Chang, Tsai-Wang, Horváth, Zsolt, Coccia-Portugal, Maria, Domont, Julien, Tseng, Ling-Min, Kunz, Georg, Sohn, Joo Hyuk, Semiglazov, Vladimir, Lerzo, Guillermo, Palacova, Marketa, Probachai, Volodymyr, Pusztai, Lajos, Untch, Michael, Gelber, Richard D, Piccart-Gebhart, Martine
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5705192/
https://ncbi.nlm.nih.gov/pubmed/22257673
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)61847-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados